ArticleInternational journal of clinical oncology2026
Adverse event-related discontinuation of maintenance Bacillus Calmette-Guérin therapy and oncological outcomes in non-muscle-invasive bladder cancer.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMaintenance Bacillus Calmette-Guérin (BCG) therapy is a key component of treatment for intermediate-risk to high-risk non-muscle-invasive bladder cancer (NMIBC) and an essential backbone for combination immunotherapy. However, its implementation remains limited by concerns regarding adverse events (AEs). We evaluated the association between AE-related discontinuation of maintenance BCG therapy and oncological outcomes.
methodsWe retrospectively investigated 228 patients with NMIBC who had received adequate induction BCG and were subsequently scheduled to receive 1 year of maintenance BCG therapy between 2007 and 2020. Patients were categorized into an AE-related discontinuation group, a discontinuation for other reasons group, and a maintenance completion group. Recurrence-free survival (RFS) was assessed using Kaplan-Meier curves. Confounding and time-dependent bias were addressed by propensity score matching and landmark analyses at 3, 6, and 12 months.
resultsOverall, 108 patients discontinued maintenance BCG because of AEs, 38 discontinued for other reasons, and 82 completed therapy (completion rate, 36%). Five-year RFS did not differ significantly between the AE-related discontinuation group and the maintenance completion group (89.4% vs. 83.5%, p = 0.314). No significant difference in RFS was observed after propensity score matching (p = 0.46). Landmark analyses consistently showed that AE-related discontinuation was not associated with an increased risk of recurrence.
conclusionsAmong patients who had received adequate induction BCG and predominantly achieved adequate BCG exposure, AE-related discontinuation of maintenance BCG was not significantly associated with worse oncological outcomes. Concerns regarding tolerability should not necessarily preclude initiation of maintenance BCG.
Indexed as
Identifiers
42687062What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.